Pharma BD Deal Intelligence
Premium-priced but strategically coherent immunology bolt-on
Full analysis, sources & comparables →argenx SE agreed on 2026-07-27 to acquire Forte Biosciences, Inc. via an all-cash tender offer of $77.00 per share, valuing Forte at approximately $2.2 billion in equity value. The transaction adds FB102, a first-in-class anti-CD122 antibody, to argenx's immunology pipeline. Forte reported positive Phase 1b vitiligo data on 2026-07-09; the offer represents an approximately 86% premium to Forte's volume-weighted average price since that readout. FB102 has clinical proof-of-concept in vitiligo and celiac disease. The tender offer is not subject to a financing condition and will be funded from cash on hand; closing is conditioned on a majority of shares tendered and expiration of the HSR waiting period.
Vitiligo is a chronic autoimmune depigmenting disorder in which cytotoxic CD8+ T cells destroy epidermal melanocytes, producing well-demarcated white macules. IL-15 signalling through the CD122 receptor subunit sustains the tissue-resident memory T cells that drive relapse, which is the mechanistic rationale for anti-CD122 blockade.
Approved/late-stage competition is dominated by JAK inhibitors: ruxolitinib cream (Opzelura, Incyte; JAK1/2 inhibition) is the only FDA-approved repigmentation therapy, with oral ritlecitinib (Pfizer; JAK3/TEC) and upadacitinib (AbbVie; JAK1) in development. FB102 differentiates by targeting IL-15/IL-2 signalling upstream at CD122 rather than broadly inhibiting JAK-dependent cytokine signalling.
Forte Biosciences reported positive Phase 1b results for FB102 in vitiligo. argenx's subsequent offer represented an approximately 86% premium to Forte's volume-weighted average price since this readout.
argenx will commence an all-cash tender offer for all outstanding Forte shares at $77.00 per share, an equity value of approximately $2.2 billion. The transaction carries no financing condition and is funded entirely from cash on hand, adding first-in-class anti-CD122 antibody FB102 to argenx's immunology pipeline.
argenx pays a full premium for de-risked Phase 1b proof-of-concept in two indications, but the deal diversifies a franchise concentrated in FcRn blockade (Vyvgart) into a distinct autoimmune mechanism, and is funded without dilution or new debt.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| argenx SE / Forte Biosciences, Inc. (this deal) | 2026 | $2.2B | 66 |
| Arcturus Therapeutics, Inc. / CSL Seqirus (CSL Limited) | 2026 | $28M | 100 |
| Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. | 2026 | $1.0B | 100 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2026 | $2.3B | 100 |
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. | 2026 | $2.5B | 75 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd | 2026 | $1.5B | 73 |
← Browse all deals · How we score deals
More: 2026 deals